BC Week In Review | Oct 19, 2018
Company News

Gurnet to acquire Corium as it heads for NDA

Healthcare investor Gurnet Point Capital will acquire drug delivery company Corium International Inc. (NASDAQ:CORI) for $12.50 per share in cash plus $0.50 per share in a contingent value right (CVR). The deal, including the CVR,...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Feb 15, 2016
Clinical News

Corplex Donepezil Transdermal System: Phase I data

Top-line data from an open-label, crossover, Australian Phase I trial in 9 healthy volunteers ages 50-80 showed that the Corplex Donepezil Transdermal System targeted to deliver 5 mg/day of donepezil and worn for 7 days...
BC Week In Review | Sep 7, 2015
Clinical News

Corplex Donepezil Transdermal System: Phase I started

Corium began an open-label, crossover, Australian Phase I trial to compare 2 formulations of the Corplex Donepezil Transdermal System worn for 7 days vs. oral Aricept donepezil for 7 days in 12 healthy volunteers ages...
Items per page:
1 - 5 of 5